← Back to patent-cliff list
NS-041
Tier C — Watch / tradeNS-041
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：KCNQ2, KCNQ3
Indications (approved)：Seizure, Depressive disorder, Epilepsy, Major depressive disorder
Regional status
US
-
EU
-
China
Phase II
2025-07-21
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of NS-041?
Approved indications include: Seizure, Depressive disorder, Epilepsy, Major depressive disorder.
When does the NS-041 patent expire?
No public expiry year is available for NS-041 yet; this page updates once verified.
How do I get a quote for NS-041 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30